Neonatal hypoxic ischemic encephalopathy: an update on disease pathogenesis and treatment.

Yildiz E., Ekici B., Tatli B.

Expert review of neurotherapeutics, cilt.17, sa.5, ss.449-459, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1080/14737175.2017.1259567
  • Dergi Adı: Expert review of neurotherapeutics
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.449-459
  • Anahtar Kelimeler: Hypoxic ischemic encephalopathy, neuroprotectives, hypothermia, erythropoietin, WHOLE-BODY HYPOTHERMIA, ANTENATAL MAGNESIUM-SULFATE, GLOBAL CEREBRAL-ISCHEMIA, PLACEBO-CONTROLLED TRIAL, BLOOD MONONUCLEAR-CELLS, DEVELOPING RAT-BRAIN, PERINATAL ASPHYXIA, THERAPEUTIC HYPOTHERMIA, FETAL SHEEP, CORD BLOOD
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: Hypoxic ischemic encephalopathy (HIE) is the most important reason for morbidity and mortality in term-born infants. Understanding pathophysiology of the brain damage is essential for the early detection of patients with high risk for HIE and development of strategies for their treatments.Areas covered: This review discusses pathophysiology of the neonatal HIE and its treatment options, including hypothermia, melatonin, allopurinol, topiramate, erythropoietin, N-acetylcyctein, magnesium sulphate and xenon.Expert commentary: Several clinical studies have been performed in order to decrease the risk of brain injury due to difficulties in the early diagnosis and treatment, and to develop strategies for better long-term outcomes. Although currently standard treatment methods include therapeutic hypothermia for neonates with moderate to severe HIE, new supportive options are needed to enhance neuroprotective effects of the hypothermia, which should aim to reduce production of the free radicals and to have anti-inflammatory and anti-apoptotic actions.